Inclusion Criteria:
  -  Received liver transplant for treatment of hATTR amyloidosis ≥12 months before study start
  -  Has increase in polyneuropathy disability (PND) score after liver transplant
  -  Has received stable immunosuppressive regimen with ≤10 mg/day of prednisone for at least 3 months before study start
  -  Has Karnofsky Performance Status (KPS) of ≥70%
  -  Has vitamin A level greater than or equal to lower limit of normal
Exclusion Criteria:
  -  Has previously received inotersen or patisiran
  -  Has clinically significant liver function test abnormalities
  -  Has known portal hypertension with ascites
  -  Has estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73 m^2
  -  Has known leptomeningeal amyloidosis
  -  Has infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
  -  Has New York Heart Association heart failure classification of >2
  -  Is wheelchair bound or bedridden
  -  Has received organ transplants other than liver transplant
  -  Will be using an other tetramer stabilizer during the study